Fundraising Fox
Find your path to Karen
Sign up to see every warm intro you have to Karen
- Paths you didn't know you had: your email and LinkedIn already hold routes to Karen. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
About
Karen Wagner is a Managing Partner at Ysios Capital, where she works on therapeutic investments and helps identify and evaluate opportunities. She joined Ysios in 2008 after more than a decade in biotech and pharma business development, having begun her career as a management consultant in McKinsey & Company's healthcare practice and later served as Director of Business Development at Ingenium Pharmaceuticals. She previously worked at Glycart Biotechnology and, following its acquisition by F. Hoffmann-La Roche, led business development and alliance management at Roche; she holds a Master's in Molecular Biology and a PhD in Cell Biology from the University of Konstanz.
Contact· self-published, not guessed
Invests in
Biotech
Investments
Board seats
AELIX TherapeuticsCardozCytoki PharmaGalectoKala PharmaceuticalsMinoryx TherapeuticsSparingVisionSynendosVivet TherapeuticsXeltis
Investor
Cytoki PharmaGalectoKALA BIO
Sources: the firm's website · curated public sources.
Colleagues at Ysios Capital
Network2
Investors connected to Karen in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Karen Wagner?
- Karen Wagner is a Managing Partner at Ysios Capital, where she works on therapeutic investments and helps identify and evaluate opportunities. She joined Ysios in 2008 after more than a decade in biotech and pharma business development, having begun her career as a management consultant in McKinsey & Company's healthcare practice and later served as Director of Business Development at Ingenium Pharmaceuticals. She previously worked at Glycart Biotechnology and, following its acquisition by F. Hoffmann-La Roche, led business development and alliance management at Roche; she holds a Master's in Molecular Biology and a PhD in Cell Biology from the University of Konstanz.
- Where does Karen Wagner work?
- Karen Wagner is General Partner at Ysios Capital.
- What does Karen Wagner invest in?
- Karen Wagner invests in Biotech.
- What check size does Karen Wagner write?
- Karen Wagner typically writes checks of $1M – $7.5M.
- What boards does Karen Wagner sit on?
- Karen Wagner holds tracked board seats at AELIX Therapeutics, Cardoz, Cytoki Pharma, Galecto, Kala Pharmaceuticals, Minoryx Therapeutics, SparingVision, Synendos, Vivet Therapeutics, Xeltis.
- What companies has Karen Wagner invested in?
- Investments tracked here include Cytoki Pharma, Galecto, KALA BIO.
About this profile. Compiled from public sources — Ysios Capital's own website and public professional profiles — and summarised by Fundraising Fox; every fact is kept with where it came from. Spotted an error, or would rather not be listed? Email privacy@fundraisingfox.com · How we build profiles · Your rights